Can Cosentyx (secukinumab) reduce vaccine protection?
Cosentyx (secukinumab) targets IL‑17A, a pathway involved in immune responses. Because of how it works, it can blunt the immune system’s response to infections and can also reduce the strength of antibody responses after some vaccines. The practical takeaway is that vaccine protection may be weaker or slower to develop while on Cosentyx, especially for vaccines that require a strong immune response to work well.
Which vaccines are affected most?
The biggest concern with immunomodulating drugs is usually for live vaccines and for vaccines that rely on robust antibody generation. Patients on biologics like Cosentyx should generally avoid live vaccines unless their clinician specifically approves them. Inactivated vaccines are typically still allowed, but they may produce a smaller or less durable immune response than in people not taking immune-suppressing therapy.
What should patients do before getting vaccinated on Cosentyx?
If vaccination is planned, clinicians often consider:
- Timing the shot when feasible relative to biologic dosing schedules.
- Using inactivated vaccines when appropriate.
- Checking whether a vaccine is live or non-live.
- Discussing any increased risk based on the patient’s age, comorbidities, and underlying condition.
This is especially important for vaccines needed for travel, workplace requirements, or seasonal outbreaks.
Does the answer differ by vaccine type (flu, COVID-19, shingles)?
Yes. Different vaccines generate protection through different immune pathways, so the degree of reduced response can vary by vaccine. In real-world guidance, non-live vaccines (including many routine adult vaccines such as flu and others) are usually recommended but may not generate the same level of protection as in untreated patients. Live vaccines are the category most often limited or avoided on therapy.
What about people who already had vaccines before starting Cosentyx?
Protection from vaccines taken before starting Cosentyx can still persist, but over time the level of protection may decline, and booster doses may be considered depending on the vaccine, how long ago it was given, and the patient’s risk.
Should patients stop or delay Cosentyx for vaccination?
Patients should not stop Cosentyx on their own. Clinicians may adjust timing case-by-case to optimize vaccine response while balancing disease control (for example, psoriasis symptoms or other autoimmune activity). The safest approach is to coordinate with the prescribing specialist and the vaccination provider.
If you tell me which vaccine you mean (for example flu, COVID-19, shingles, pneumonia, or travel vaccines) and whether it is a live or non-live shot, I can narrow the answer to that specific vaccine scenario.